(firstQuint)Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors.

 This study ams to evaluate the safety, tolerability, and pharmacokinetics of ISU104 in patients with advanced solid tumors.

 Primary objective To determine recommended Phase II dose (RP2D) of ISU104 based on the results of its safety and tolerability in patients with advanced solid tumors.

 Secondary objectives 1.

 To evaluate the pharmacokinetics (PK) of ISU104 in patients with advanced solid tumors.

 2.

 To evaluate tumor response profile of ISU104 in patients with advanced solid tumors.

 Exploratory purpose To identify the expression of explorable multiple tumor biomarkers and to analyze the relationship between these biomarkers and antitumor activity.

.

 Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors@highlight

A phase I, open-label, dose-finding study to assess the safety, tolerability and pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with advanced solid tumors.

